<SEC-DOCUMENT>0000320017-17-000094.txt : 20171109
<SEC-HEADER>0000320017-17-000094.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171109161659
ACCESSION NUMBER:		0000320017-17-000094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CALADRIUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		171191049

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-842-0100

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-k3q2017pr110917.htm
<DESCRIPTION>8-K 11.09.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sf4ef01034aa2472a802a146828cb3643"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported): November 9, 2017</font></div><div style="line-height:120%;text-align:center;"><img src="caladriuslogoa10.jpg" alt="caladriuslogoa10.jpg" style="height:52px;width:148px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;CALADRIUS BIOSCIENCES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in Charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-33650</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-2343568</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">110 Allen Road, Second Floor, Basking Ridge, NJ 07920</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)(Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(908) 842-0100</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's Telephone Number</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sbc7a689755f84da7adaf84ca37c80d7e"></a></div><div style="line-height:120%;padding-bottom:15px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations and Financial Condition.</font></div><div style="line-height:120%;padding-bottom:33px;text-align:justify;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in Item 7.01 is incorporated by reference.</font></div><div style="line-height:120%;padding-bottom:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation FD Disclosure.</font></div><div style="line-height:120%;padding-bottom:15px;text-align:justify;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 9, 2017, Caladrius Biosciences, Inc. (the "Company") issued a press release in connection with its 2017 Third Quarter Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.</font></div><div style="line-height:120%;padding-bottom:15px;text-align:justify;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will conduct a conference call to review its financial results on November 9, 2017 at 4:30 p.m. Eastern Standard Time.</font></div><div style="line-height:120%;padding-bottom:33px;text-align:justify;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.75%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a3q2017pressrelease.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release, dated November 9, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s56b52824de494f4f8f32d20aedde3081"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly&#160;caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:22%;"></td><td style="width:23%;"></td><td style="width:9%;"></td><td style="width:32%;"></td><td style="width:14%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CALADRIUS BIOSCIENCES, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David J. Mazzo</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David J. Mazzo, PhD</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:  November 9, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a3q2017pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s38036f45250e4542ae1b6e82d966f4b0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caladrius Biosciences Reports 2017 Third Quarter Results</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conference call begins today at 4:30 p.m. Eastern Time</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASKING RIDGE, N.J., (November 9, 2017) - Caladrius Biosciences, Inc. (NASDAQ: CLBS)</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Caladrius&#8221; or the &#8220;Company&#8221;), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications,&#160;announces results for the three and nine months ended September 30, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highlights of the 2017 third quarter and recent weeks include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enrolled the 70</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;subject in The Sanford Project: T-Rex Study (the &#8220;T-Rex Study&#8221;), a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes (&#8220;T1D&#8221;), which triggered a $2.4 million milestone payment and the delivery of 508,475 shares of Caladrius common stock as per the terms of the September 2016 private placements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reached 50% of subjects, or 56 patients, treated in the T-Rex Study, which establishes a timeframe for a prescribed interim analysis when the first 56 patients reach their 6-month follow-up visit; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded approximately $2 million as a Small Business Innovative Research (&#8220;SBIR&#8221;) grant from the National Heart, Lung and Blood Institute of the National Institutes of Health (&#8220;NIH&#8221;) to support a Phase 2 clinical study with CLBS14 in patients with coronary microvascular dysfunction (&#8220;CMD&#8221;).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management Commentary</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Throughout the third quarter and following the sale of our contract manufacturing business to Hitachi Chemical, we made significant progress advancing Caladrius as a purely development-focused biopharmaceutical company and achieved key milestones in a number of our clinical development programs,&#8221; stated David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius.  &#8220;Our lead program, the T-Rex study, remains on track to complete enrollment by the end of this year.  Additionally, we expect to have the results of a planned pre-specified interim analysis of the data from the six-month follow-up of the first 56 patients around the end of the first quarter of 2018.&#8221;   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Furthermore, we continue to execute according to our strategy to advance our pipeline programs with collaborative support, such as grants, partnerships or licensing.  During the third quarter 2017, we were pleased to receive an NIH grant to help fund our Phase 2 study of CLBS14 in CMD.  We also continue to receive funding from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) grant in support of the T-Rex study,&#8221; Dr. Mazzo continued. &#8220;The successful sale of our PCT manufacturing subsidiary earlier this year has resulted in Caladrius being well-funded and focused on advancing our clinical development programs, while also allowing us to opportunistically explore compelling therapeutic prospects through a comprehensive, disciplined and data-driven process. We look forward to achieving a number of value-creating milestones during the remainder of the year and into 2018.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Third Quarter Financial Highlights </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note: Effective with the sale of PCT to Hitachi in the second quarter of 2017, all PCT-related activities and gain on sale results will be reported as discontinued operations.  All remaining operations will be reported as continuing operations.  In addition, all prior year comparative financial results will restate PCT operations as discontinued operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development (R&amp;D) expenses for the third quarter of 2017 of $3.2 million increased 8% compared with $3.0 million in the third quarter of 2016, as the Company focuses its R&amp;D efforts on the ongoing Phase 2 T-Rex Study and preparations for other pipeline programs.  Caladrius&#8217; clinical development programs are supported, in part, by grants and collaborations.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative (G&amp;A) expenses for the third quarter of 2017 remained flat at $2.9 million, compared with $2.8 million in the third quarter of 2016.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net loss from continuing operations for the third quarter of 2017 was $3.5 million, compared with the net loss from continuing operations of $6.1 million for the comparable 2016 period.  The continuing operations net loss includes a tax benefit of $2.4 million, which partially offsets the tax expense reported in discontinued operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations during the third quarter of 2016 was $1.2 million.  Discontinued operations relate to our sale of PCT to Hitachi in the second quarter of 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share from continuing operations attributable to Caladrius common stockholders for the third quarter of 2017 was $0.38 per share compared to net loss per share of $0.95 for the same period in 2016. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Month Financial Highlights </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D expenses for the first nine months of 2017 decreased 17% to $11.2 million compared with $13.5 million for the same period in 2016.  G&amp;A expenses were $9.1 million for the first nine months of 2017 compared with $10.5 million for first nine months of 2016. The first nine months of 2017 included $1.7 million of equity compensation expense. This unusually high expense was due to the acceleration of employee equity stock and option award vesting triggered by the sale of the Company&#8217;s PCT subsidiary to Hitachi. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net loss from continuing operations for the nine months ended September 30, 2017 was $12.2 million, compared with the net loss from continuing operations of $25.6 million for the same period of 2016.  The continuing operations net loss includes a tax benefit of $8.3 million, which partially offsets the tax expense reported in discontinued operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations during the first nine months of 2017 was $37.3 million, which includes a $40.2 million gain on the sale of PCT (net of $11.6 million taxes), compared with a loss from discontinued operations of $1.6 million in the same period in 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share from continuing operations attributable to Caladrius common stockholders for the nine months ended September 30, 2017 was $1.37 per share compared to net loss per share of $4.23 for the same period in 2016. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Highlights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2017, Caladrius had cash, cash equivalents and marketable securities of $59.4 million compared with $7.1 million as of December 31, 2016. During the third quarter of 2017, the Company received an additional $4.4 million as a final net cash settlement of the PCT transaction, bringing the total received to $79.4 million. Also during the third quarter of 2017, upon the enrollment of the 70</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;patient in the T-Rex study, the Company received $2.4 million and delivered 508,475 shares of Caladrius common stock as per the terms of the September 2016 private placements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on existing programs and projections, the Company expects to have more than $50 million in cash and marketable securities at year-end 2017. Caladrius also expects less than $5 million of CLBS03 external spending obligations after 2017 to reach the completion of the T-Rex study, excluding any further CIRM funding. The Company is confident its cash balances and additional grant funding, along with continued disciplined expense management, will allow it to fund its current business plan beyond 2018.    </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conference Call</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius&#8217; management will host a conference call for the investment community beginning today at 4:30 p.m. Eastern Time to review financial results, provide a Company update and answer questions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders and other interested parties may participate in the conference call by dialing 877-562-4460 (U.S.) or 513-438-4106 (international) and providing conference ID 6198497. The call will also be broadcast live on the Company&#8217;s website at </font><font style="font-family:inherit;font-size:10pt;color:#0094b3;">www.caladrius.com/events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The webcast will be archived on the Company&#8217;s website for 90 days.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Caladrius Biosciences</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2 trial.  CLBS14, CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius&#8217; proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia.  A phase 2 study of CLBS12 as a treatment for critical limb </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ischemia is about to initiate in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan&#8217;s progressive regenerative medicine regulations.  &#160;For more information about Caladrius please visit&#160;</font><font style="font-family:inherit;font-size:10pt;color:#0094b3;">www.caladrius.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor for Forward Looking Statements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management&#8217;s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company&#8217;s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the &#8220;Risk Factors&#8221; described in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 17, 2017, and in the Company&#8217;s other periodic filings with the SEC. The Company&#8217;s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Caladrius does not intend, and disclaims any obligation, to update or revise any forward-looking information contained in this Press Release or with respect to the matters described herein.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John Menditto</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Director, Investor Relations and Corporate Communications</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phone:  908-842-0084</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Email: jmenditto@caladrius.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LHA Investor Relations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anne Marie Fields</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phone: 212-838-3777</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Email: afields@lhai.com&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Media:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius Biosciences, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Terrance Beckett</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Communications and Marketing</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phone: 646-434-2681</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Email: tbeckett@caladrius.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">-Tables to Follow-</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:53%;"></td><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:11%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caladrius Biosciences, Inc.</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Financial Data (unaudited)</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended Sept 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended Sept 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Statement of Operations Data:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,187 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,959 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11,191 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,496 </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">General and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,943 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,769 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,082 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,514 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,130 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,728 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,273 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,010 </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6,130)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5,728)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(20,273)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(24,010)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;177 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;137 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20 </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(368)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(372)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,601)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss before income taxes and noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5,962)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6,091)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(20,508)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,591)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Benefit from income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,414)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(8,301)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3,548)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6,091)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12,206)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,591)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,197)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;37,330 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,629)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3,548)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,288)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,124 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,220)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less - net loss from continuing operations attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(119)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(59)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(150)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(187)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less - net income (loss) from discontinued operations attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(346)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(568)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(335)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net income (loss) attributable to Caladrius Biosciences, Inc. common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$     (3,429)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$     (6,883)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$     25,842 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$    (26,698)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$       (0.38)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$       (0.95)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$      (1.37)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$        (4.23)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Discontinued operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$       (0.13)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$         4.30 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$        (0.22)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Caladrius Biosciences, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.38)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(1.09)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2.94 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(4.45)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted average common shares outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,094 </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,323 </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,804 </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,002 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$     59,449 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$       7,077 </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;67,555 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;53,514 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,575 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,048 </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;52,980 </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,066 </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>caladriuslogoa10.jpg
<TEXT>
begin 644 caladriuslogoa10.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" "" 70# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            <)" H$!08# @'_Q  < 0$  @,! 0$
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M.7XQAN<*6]'G]UC^@' ]/B(=[@<[S^I=T6?^GZ
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M%\81+D;BG<') U)PS^*9$H<4*5":J3D)OC^'\:Y.PO1YSPV)W#B5<D6Y<')
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MXIJ=J9-V:F>I4=Z:DH\J^;>JB,X\\FM_=VX?P;,MK*;+J]J'HLLQC*"6175
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M=*CCJ= 9DWZ+-I*W*E=X&TD$ @CD>7<__\0 7Q$  @( ! ,#!0<-"P8+"0
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M4'4!HY!Y4;@,-5W(V&YGR?GRAW&SW9Y)@O-P?$MB65ET\:Q)7G%>O+L4WYB
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M24'*>KIU.E)C!RO=LW1!::QQR+_2>8?\K#\8?\H9K[2?QSA_P<3]OXKCG?\
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M8N8GV5<NT[4U%5ZQ]*UEKH"#7C-B8(DTT"U<-8N.J]C"6IJ22P^!56Y(Y=9
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M @,0(C$"(QV@1B-(B(]41':/Y+?_ *1B_M2GQKX&EIIY^&1II_8\N.CR_P!
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M!M^-[--.*OA*M:KU0@V^'0I/5/68WLZ8CO+3MN+6=.,2V5A+0IWH!DB,F$%
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MJOF4CN,P.)?Y"WX1_&(=+M600Y EX>SX"N08907H:*Z'F,)>#'02?AQP&WA
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MOR,5,2+46M!B8:?#Z@\Y(T2!/@,RX[FFEDN#6NC&@*:HK,@&;H2$HE1,E#V
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M  P# 0 "  ,    0               GJYX                    8P:0
M         H     %8 #$=           '      ' %=48           X
M   X "@      #7@'_#'"3- NMO!PCD8 QJ9=E PH%@XS"JXHPYW&5Q &TX%
M40 %^R'&!CNH 7: "N( VU,H@ %/Z0XVD_D 'AX 5O %M2F:H ^ "'!H!YX
M;/ "NF"#  3!PQ ^H8Z$X'MV=P >"9R#AHH%R"V%  I]('[     &$ '!8
M                               "3XN_(7MC'B=',          >9RB8
M9FI3;,%JH         'J-D">FV="TSMH          1+;O'1GX\L\^C'_\0
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M($]U]WF* ;9.(M@(P>;-*JCA+J6 SO[$2>7.)O B@S0Z&> AT H:N-3M)18
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M.^?&#@FF;Y0#V+T(/*/08,D(,4A 74_%9;1J,8W$?*5&$/ED/"L4K'CJ(FN
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M]PC*4EBQ<\ B4'#GSL6(!70 3M(!>-_- BMG#X%EG&JXA>1 2DY387Q*2&
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M5!H*S@6:5$&3:"Z$K0.>"3..<84B*!$0^/_$ "80 0$! 0 " @(" 04!
M  $1(0 0,2!!,%% 4)%@87&QT?#_V@ ( 0$  3\0_G#Q?X K3X)%=%D.?FQ+
M[0'!K=H4-*2"LI57N;,H*G(F<L %00 *J@ JSD$ZY*]&^- !S%H@@JT6"=$E
MQO\ 6W!X'L%'%O\ U00,=41#BS?L<SE<L9&]0[S%G R!)/YOC4K\_P!>^>"[
ME,/>>-I/%](:@$X;J4+ " ;+1;"Z-4H3^,3--W]-,)^7"4:3QC,LQ) X!*$/
MG4FG:6EP1\0^]22X8JYU8(9-8$$HP^.D8;Y"2)4(G",W?QKSQ8V:"'-U)D,W
M+._JA/D$!]ZC.:J?E)F*@#J!VT ,K"A=42%YH@.P -;= L& O,HN)D&?C_%W
M@P6:#1*TA2BGN* ,&/5P!K()@/ZKU&<LF<. $0$ HB(BB3O_ %G81>1'[7\Y
MS8342_#)P1>7],DP>/C<:=1NS<1P1K!'3UT#T4] I1TV\14>*F7B4FRZA>9%
M4?XJ"_T*P#A;3@8@Q(1B/@?$I3POJF C8(Q=0S4_6\M\GNYV(G#A7/A[#P O
MZ.N>?K3PGXN<)7QD?F]/'OA*/$D"RP;9#):./</YI36**#6NZ<S8*4-6?67F
M$_8;DO4FB,,\1U9$O$ :"E9C589*8-:#.P04&]A(BXGT^#/:\\IM"F:E%CHY
M"9RWYHK=/+33*&':NO6HEF5T$C[ 9.J"\ 2V\2)X()!$->D2GAN?N>:E;BUM
M.\+$Q)7P0(JA2E!F=5D$T?JN+*Q 7SX(!,<^O]0KU!XY96H9T8-*9U)HS" 6
M&Z^J!_);:E?Y*IZ^T_OKC#\%'M'7I02!!:&RW72Q8K4 SE;?"H[%2!7=QRK>
M).@06#P08^0 Q.)X2$**)UWD_E7T8[     (!@!Z ^@\.I=JG@%]^NGCPDHE
MI/GF!E]>0+=7=R(#."FIHZ113BN3/@G#^E#XX$^.;BMUO! (<$'A^%A#EL"!
M^'?)8C"<]IF6$&](%3VS-?\ P&CF9(2#MXKX/4+K%BN*$E1E,.>X8A2 V<F
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ATJ[\^>M<6=D$"0"O8^KWW"=8#0S>*R1HOO$QYQ0QW__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
